Contradictory data have been reported concerning neuropsychiatric side effects of the first-line antiretroviral drug dolutegravir, which may be partly due to lack of control groups or psychiatric assessment tools. This dataset report BIS-11, DASS-42, MATE-Q scores of 194 people living with HIV receiving dolutegravir-containing treatment (82/194) or alternative treatment (112/194).The results from this database have been published and are available at:Van de Wijer, L., et al., Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV. AIDS Behav, 2021. https://doi.org/10.1007/s10461-021-03272-2